Table 1 Characteristics with malignant ovarian germ cell tumor patients
From: Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study
Variables | Training cohort No. (%) | External validation cohort No. (%) | P-value |
|---|---|---|---|
Total | 1401 | 121 | |
Age (years) | 0.066 | ||
≤ 27 | 942 (67.24%) | 70 (57.85%) | |
28–38 | 304 (21.70%) | 37 (30.58%) | |
≥ 39 | 155 (11.06%) | 14 (11.57%) | |
Tumor size (mm) | 0.863 | ||
≤ 130 | 533 (38.04%) | 47 (38.84%) | |
131–175 | 367 (26.20%) | 29 (23.97%) | |
≥ 176 | 501 (35.76%) | 45 (37.19%) | |
FIGO Stage | 0.537 | ||
FIGO Stage I | 964 (68.81%) | 81 (66.94%) | |
FIGO Stage II | 99 (7.07%) | 12 (9.92%) | |
FIGO Stage III | 264 (18.84%) | 24 (19.83%) | |
FIGO Stage IV | 74 (5.28%) | 4 (3.31%) | |
Laterality | 0.482 | ||
Only one side | 1349 (96.29%) | 119 (98.35%) | |
Both sides | 48 (3.43%) | 2 (1.65%) | |
Unkown | 4 (0.29%) | 0 (0.00%) | |
Histological subtype | 0.016 | ||
Dysgerminoma | 405 (28.91%) | 38 (31.40%) | |
Yolk sac tumor | 207 (14.78%) | 19 (15.70%) | |
Teratocarcinoma | 771 (55.03%) | 63 (52.07%) | |
Non-gestational choriocarcinoma | 18 (1.28%) | 1 (0.83%) | |
Grade | 0.941 | ||
Grade I | 120 (8.57%) | 9 (7.44%) | |
Grade II | 172 (12.28%) | 16 (13.22%) | |
Grade III | 216 (15.42%) | 18 (14.88%) | |
Grade IV | 91 (6.50%) | 6 (4.96%) | |
Unkown | 802 (57.24%) | 72 (59.50%) | |
Surgery | 0.117 | ||
No | 13 (0.93%) | 3 (2.48%) | |
Local resection | 724 (51.68%) | 69 (57.02%) | |
Debulking or cytoreductive surgery or pelvic exenteration | 664 (47.39%) | 49 (40.50%) | |
Radiation | 0.559 | ||
No | 1391 (99.29%) | 119 (98.35%) | |
Yes | 10 (0.71%) | 2 (1.65%) | |
Chemotherapy | 0.568 | ||
No | 593 (42.33%) | 55 (45.45%) | |
Yes | 808 (57.67%) | 66 (54.55%) |